The Cost of Control: Financial and Administrative Burdens of Limited Distribution Network Changes in Cystic Fibrosis.

IF 2.4 3区医学 Q1 PEDIATRICS

Pediatric Pulmonology Pub Date : 2026-09-01 DOI:10.1002/ppul.71829

Brittany A Wright, Cameron J McKinzie, Charissa W Kam, Casey R Tak, Lynnsey M Knockel, Julie Langhorst, Rebecca S Pettit, Lynda Roe, Billie Simonson, Hilary Vogt, Nicole Willer, David C Young

{"title":"The Cost of Control: Financial and Administrative Burdens of Limited Distribution Network Changes in Cystic Fibrosis.","authors":"Brittany A Wright, Cameron J McKinzie, Charissa W Kam, Casey R Tak, Lynnsey M Knockel, Julie Langhorst, Rebecca S Pettit, Lynda Roe, Billie Simonson, Hilary Vogt, Nicole Willer, David C Young","doi":"10.1002/ppul.71829","DOIUrl":null,"url":null,"abstract":"Background: The clinical impact of pharmacists and pharmacy technicians on the care of people with cystic fibrosis (pwCF) has been well documented within the literature, including medication access, reduction of hospitalizations, and consolidation of pharmaceutical delivery for pwCF with complex medication regimens. However, challenges related to access and affordability have become increasingly complex, increasing the administrative burden placed upon these members of the multidisciplinary CF care team. The goal of this study was to quantify the time pharmacists and pharmacy technicians at CF Foundation-accredited care centers (CFACC) spent triaging and resolving errors, categorize the types of interventions required, and tabulate the financial burden for pwCF averted through these interventions.Methods: This study was a retrospective review of pharmacy team members' interactions following a change in limited distribution network of cystic fibrosis transmembrane conductance regulator modulators (CFTRm) over a 4-month period of time. Each site received institutional review board exemption. Measures were characterized using descriptive statistics and were analyzed in SAS v9.4 (Cary, NC). Collected data were extrapolated to be nationally representative based on the 2023 CFF Patient Registry report.Results: Six CFACC and 1781 pwCF were included in this review. Of these pwCF, 216 required additional interventions following a required change in the dispensing pharmacy for their CFTRm. Collectively, 201.5 h were spent on resolution of issues during the study period with interventions successfully averting a financial burden to pwCF of $226,094.73. Extrapolations of time and financial burden were estimated to be 3700 h and over $4.2 million, respectively.Conclusions: Medication access and affordability continue to present significant barriers for pwCF. We aim to highlight the critical services provided by clinical pharmacy teams at CFACC as well as their integrated health-system specialty pharmacies, and the vital role they play in improving outcomes and providing cost-effective care for pwCF.","PeriodicalId":19932,"journal":{"name":"Pediatric Pulmonology","volume":"61 9","pages":"e71829"},"PeriodicalIF":2.4000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13572961/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Pulmonology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ppul.71829","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The clinical impact of pharmacists and pharmacy technicians on the care of people with cystic fibrosis (pwCF) has been well documented within the literature, including medication access, reduction of hospitalizations, and consolidation of pharmaceutical delivery for pwCF with complex medication regimens. However, challenges related to access and affordability have become increasingly complex, increasing the administrative burden placed upon these members of the multidisciplinary CF care team. The goal of this study was to quantify the time pharmacists and pharmacy technicians at CF Foundation-accredited care centers (CFACC) spent triaging and resolving errors, categorize the types of interventions required, and tabulate the financial burden for pwCF averted through these interventions.

Methods: This study was a retrospective review of pharmacy team members' interactions following a change in limited distribution network of cystic fibrosis transmembrane conductance regulator modulators (CFTRm) over a 4-month period of time. Each site received institutional review board exemption. Measures were characterized using descriptive statistics and were analyzed in SAS v9.4 (Cary, NC). Collected data were extrapolated to be nationally representative based on the 2023 CFF Patient Registry report.

Results: Six CFACC and 1781 pwCF were included in this review. Of these pwCF, 216 required additional interventions following a required change in the dispensing pharmacy for their CFTRm. Collectively, 201.5 h were spent on resolution of issues during the study period with interventions successfully averting a financial burden to pwCF of $226,094.73. Extrapolations of time and financial burden were estimated to be 3700 h and over $4.2 million, respectively.

Conclusions: Medication access and affordability continue to present significant barriers for pwCF. We aim to highlight the critical services provided by clinical pharmacy teams at CFACC as well as their integrated health-system specialty pharmacies, and the vital role they play in improving outcomes and providing cost-effective care for pwCF.

查看原文本刊更多论文

控制成本：囊性纤维化患者有限配电网变化的财政和行政负担。

背景：药剂师和药学技术人员对囊性纤维化（pwCF）患者护理的临床影响已在文献中得到充分记录，包括药物可及性、住院率的降低和复杂用药方案下pwCF的药物输送的巩固。然而，与获取和负担能力相关的挑战变得越来越复杂，增加了多学科CF护理团队成员的行政负担。本研究的目的是量化CF基金会认可的护理中心（CFACC）的药剂师和药房技术人员在分诊和解决错误上花费的时间，对所需干预措施的类型进行分类，并通过这些干预措施避免pwCF的经济负担。方法：本研究回顾性回顾了4个月期间囊性纤维化跨膜传导调节剂（CFTRm）有限分销网络改变后药房团队成员的相互作用。每个站点都获得了机构审查委员会的豁免。测量结果采用描述性统计进行表征，并在SAS v9.4 （Cary， NC）中进行分析。收集的数据根据2023年CFF患者登记报告推断为具有全国代表性。结果：6例CFACC和1781例pwCF纳入本综述。在这些pwCF中，216名患者在其CFTRm配药药房发生必要的变化后需要额外的干预措施。在研究期间，总共花费了2015个小时来解决问题，干预措施成功地避免了pwCF的经济负担226,094.73美元。据推测，时间和财政负担分别为3700小时和420多万美元。结论：药物可及性和可负担性仍然是pwCF的重大障碍。我们的目标是突出CFACC的临床药学团队及其综合卫生系统专业药房提供的关键服务，以及他们在改善治疗结果和提供具有成本效益的护理方面发挥的重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Pulmonology 医学-呼吸系统

CiteScore

6.00

自引率

12.90%

发文量

468

审稿时长

3-8 weeks

期刊介绍： Pediatric Pulmonology (PPUL) is the foremost global journal studying the respiratory system in disease and in health as it develops from intrauterine life though adolescence to adulthood. Combining explicit and informative analysis of clinical as well as basic scientific research, PPUL provides a look at the many facets of respiratory system disorders in infants and children, ranging from pathological anatomy, developmental issues, and pathophysiology to infectious disease, asthma, cystic fibrosis, and airborne toxins. Focused attention is given to the reporting of diagnostic and therapeutic methods for neonates, preschool children, and adolescents, the enduring effects of childhood respiratory diseases, and newly described infectious diseases. PPUL concentrates on subject matters of crucial interest to specialists preparing for the Pediatric Subspecialty Examinations in the United States and other countries. With its attentive coverage and extensive clinical data, this journal is a principle source for pediatricians in practice and in training and a must have for all pediatric pulmonologists.